CY1112892T1 - Δισκιο λασοφοξιφαινης και επικαλυψη του - Google Patents

Δισκιο λασοφοξιφαινης και επικαλυψη του

Info

Publication number
CY1112892T1
CY1112892T1 CY20121100504T CY121100504T CY1112892T1 CY 1112892 T1 CY1112892 T1 CY 1112892T1 CY 20121100504 T CY20121100504 T CY 20121100504T CY 121100504 T CY121100504 T CY 121100504T CY 1112892 T1 CY1112892 T1 CY 1112892T1
Authority
CY
Cyprus
Prior art keywords
lasoxoxyphine
tablet
cover
lasofoxifene
active ingredient
Prior art date
Application number
CY20121100504T
Other languages
English (en)
Inventor
Daniel S Gierer
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of CY1112892T1 publication Critical patent/CY1112892T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Εδώ αποκαλύπτονται φαρμακευτικές συνθέσεις που έχουν ομοιόμορφη κατανομή φαρμάκου και δραστικότητα με τη χρησιμοποίηση λασοφοξιφαίνης ως ένα δραστικό συστατικό και που περιέχουν ένα διοξείδιο του πυριτίου για τη μείωση της απώλειας του δραστικού συστατικού κατά τη διάρκεια της παραγωγικής διαδικασίας και μέθοδοι για την παραγωγή τέτοιων συνθέσεων. Η επικάλυψη τριακετίνης ως πλαστικοποιητή αποδείχθηκε ότι παρέχει καλή σταθερότητα στη λασοφοξιφαίνη.
CY20121100504T 2002-07-10 2012-06-06 Δισκιο λασοφοξιφαινης και επικαλυψη του CY1112892T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39509002P 2002-07-10 2002-07-10
EP03764059A EP1534248B1 (en) 2002-07-10 2003-06-30 Lasofoxifene tablet and its coating

Publications (1)

Publication Number Publication Date
CY1112892T1 true CY1112892T1 (el) 2016-04-13

Family

ID=30115812

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100504T CY1112892T1 (el) 2002-07-10 2012-06-06 Δισκιο λασοφοξιφαινης και επικαλυψη του

Country Status (36)

Country Link
US (2) US20040057992A1 (el)
EP (1) EP1534248B1 (el)
JP (2) JP4446446B2 (el)
KR (1) KR100782693B1 (el)
CN (1) CN100344278C (el)
AP (1) AP2005003201A0 (el)
AR (1) AR040434A1 (el)
AT (1) ATE550017T1 (el)
AU (1) AU2003247017B2 (el)
BR (1) BR0312563A (el)
CA (1) CA2489407C (el)
CY (1) CY1112892T1 (el)
DK (1) DK1534248T3 (el)
EA (1) EA007268B1 (el)
EC (1) ECSP055528A (el)
ES (1) ES2395123T3 (el)
HK (1) HK1077747A1 (el)
HN (1) HN2003000206A (el)
HR (1) HRP20041196A2 (el)
IL (2) IL165746A0 (el)
IS (1) IS7594A (el)
MA (1) MA27318A1 (el)
MX (1) MXPA05000394A (el)
NO (1) NO20050018L (el)
NZ (1) NZ537278A (el)
OA (1) OA12883A (el)
PA (1) PA8576201A1 (el)
PE (1) PE20040104A1 (el)
PL (1) PL374913A1 (el)
PT (1) PT1534248E (el)
SI (1) SI1534248T1 (el)
TN (1) TNSN05006A1 (el)
TW (1) TW200406222A (el)
UY (1) UY27886A1 (el)
WO (1) WO2004006895A1 (el)
ZA (1) ZA200410196B (el)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8576201A1 (es) * 2002-07-10 2004-05-26 Pfizer Prod Inc Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
US20040253305A1 (en) * 2003-06-12 2004-12-16 Luner Paul E. Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) * 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
EP1871359A1 (en) * 2005-04-07 2008-01-02 Miso Sabovic Delaying the ageing process and disorders caused by ageing
WO2006118137A1 (ja) * 2005-04-26 2006-11-09 Dainippon Sumitomo Pharma Co., Ltd. ビグアナイド系薬物を含有する粒状製剤
GB0516604D0 (en) * 2005-08-12 2005-09-21 Sandoz Ag Rapidly dispersing/disintegrating compositions
EP3173084B1 (en) 2005-11-11 2019-10-23 Boehringer Ingelheim International GmbH Quinazoline derivatives for the treatment of cancer diseases
LT2487166T (lt) 2007-02-23 2016-11-10 Gilead Sciences, Inc. Terapinių agentų farmakokinetinių savybių moduliatoriai
CA2835910C (en) * 2007-04-25 2016-06-28 Warner Chilcott Company, Llc Improved vitamin d content uniformity in pharmaceutical dosage forms
US20100055180A1 (en) * 2007-10-10 2010-03-04 Mallinckrodt Baker, Inc. Directly Compressible Granular Microcrystalline Cellulose Based Excipient, Manufacturing Process and Use Thereof
CN101820863A (zh) * 2007-10-10 2010-09-01 马林克罗特贝克公司 直接可压制的高功能性颗粒状微晶纤维素基赋形剂、其制备方法和用途
WO2009135067A1 (en) * 2008-05-01 2009-11-05 Wyeth Pharmaceutical polish formulations
SG190618A1 (en) * 2008-05-02 2013-06-28 Gilead Sciences Inc The use of solid carrier particles to improve the processability of a pharmaceutical agent
US9545381B2 (en) * 2009-07-06 2017-01-17 Boehringer Ingelheim International Gmbh Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
RU2661402C2 (ru) * 2011-10-17 2018-07-16 Лексикон Фармасьютикалз, Инк. Твердые дозированные формы (s)-этил 2-амино-3-(4-(2-амино-6((r)-1-(4-хлор-2-(3-метил-1н-пиразол-1-ил)фенил)-2,2,2-трифторэтокси)пиримидин-4-ил)фенил)пропаноата
DK2851075T3 (da) 2012-05-14 2022-01-31 Shionogi & Co Præparat, der indeholder 6,7-umættet -7-carbamoylmorphinanderivat
PL3043778T3 (pl) * 2013-09-13 2018-04-30 Bayer Pharma Aktiengesellschaft Kompozycje farmaceutyczne zawierające refametinib
RU2539375C1 (ru) * 2013-11-07 2015-01-20 Общество С Ограниченной Ответственностью "Валента-Интеллект" Фармацевтическая композиция в форме таблетки и способ ее получения
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
CN103830196A (zh) * 2014-03-14 2014-06-04 王志刚 一种酒石酸拉索昔芬分散片及其制备方法
TWI535784B (zh) 2014-08-26 2016-06-01 財團法人工業技術研究院 剪切增稠配方、及包含其之複合材料
CN105434444B (zh) * 2014-09-29 2021-02-05 上海奥奇医药科技有限公司 一种A-失碳-5α雄甾烷化合物的口服制剂
US20190183850A1 (en) * 2016-07-25 2019-06-20 Canopy Growth Corporation New cannabis tablet formulations and compositions and methods of making the same
JP6892151B2 (ja) 2016-10-11 2021-06-23 デューク ユニバーシティ Ｅｒ＋乳がんのラソフォキシフェン処置
EP3773524A4 (en) 2018-04-10 2021-12-22 Duke University TREATMENT OF BREAST CANCER WITH LASOFOXIFEN
GB202116903D0 (en) 2021-11-18 2022-01-05 Sermonix Pharmaceuticals Inc Lasofoxifene treatment of aromatase-resistant er+ cancer
CN114288258A (zh) * 2022-02-18 2022-04-08 山东新时代药业有限公司 一种单硝酸异山梨酯片及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4182A (en) * 1845-09-09 Island
US4880636A (en) * 1988-05-13 1989-11-14 Franz Robert M Film coated tablet of ranitidine HCl
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
UA51676C2 (uk) * 1995-11-02 2002-12-16 Пфайзер Інк. (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
US6372457B1 (en) 1997-01-14 2002-04-16 Arkion Life Sciences Llc Process and materials for production of glucosamine
KR200161927Y1 (ko) * 1997-08-26 1999-12-01 윤종용 냉장고
YU26700A (sh) * 1999-05-24 2002-06-19 Pfizer Products Inc. Postupak za cis-1-(2-(4-(6-metoksi-2-fenil-1,2,3,4- tetrahidronaftalen-1-il)fenoksi)etil)pirolidin
US6436977B1 (en) * 1999-09-29 2002-08-20 Pfizer Inc. Dosing regimens for lasofoxifene
US6419956B1 (en) * 1999-12-30 2002-07-16 Ancile Pharmaceuticals Odor-masking coating for a pharmaceutical preparation
EP1145719A3 (en) * 2000-03-10 2001-11-14 Pfizer Products Inc. Use a ferrous salt for inhibiting oxidative degradation of pharmaceutical formulations
AR029538A1 (es) * 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos
OA12596A (en) * 2001-05-01 2006-06-08 Pfizer Prod Inc Method for manufacturing a low dose pharmaceuticalcomposition.
PA8576201A1 (es) * 2002-07-10 2004-05-26 Pfizer Prod Inc Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco

Also Published As

Publication number Publication date
OA12883A (en) 2006-09-15
EA200401583A1 (ru) 2005-06-30
PA8576201A1 (es) 2004-05-26
HK1077747A1 (en) 2006-02-24
MXPA05000394A (es) 2005-03-23
PL374913A1 (en) 2005-11-14
ECSP055528A (es) 2005-03-10
DK1534248T3 (da) 2012-06-25
MA27318A1 (fr) 2005-05-02
SI1534248T1 (sl) 2012-07-31
NZ537278A (en) 2007-07-27
EP1534248B1 (en) 2012-03-21
IL165746A (en) 2008-12-29
US20040057992A1 (en) 2004-03-25
TW200406222A (en) 2004-05-01
JP2005535671A (ja) 2005-11-24
CA2489407A1 (en) 2004-01-22
AU2003247017B2 (en) 2008-03-06
IL165746A0 (en) 2006-01-15
NO20050018L (no) 2005-01-12
ES2395123T3 (es) 2013-02-08
ZA200410196B (en) 2006-07-26
PE20040104A1 (es) 2004-02-27
WO2004006895A1 (en) 2004-01-22
CN1668285A (zh) 2005-09-14
AR040434A1 (es) 2005-04-06
EP1534248A1 (en) 2005-06-01
PT1534248E (pt) 2012-05-25
AP2005003201A0 (en) 2005-03-31
US20070110800A1 (en) 2007-05-17
JP4446446B2 (ja) 2010-04-07
KR100782693B1 (ko) 2007-12-07
US7553500B2 (en) 2009-06-30
ATE550017T1 (de) 2012-04-15
CN100344278C (zh) 2007-10-24
AU2003247017A1 (en) 2004-02-02
CA2489407C (en) 2009-01-27
IS7594A (is) 2004-12-13
KR20050017102A (ko) 2005-02-21
JP2007031451A (ja) 2007-02-08
EA007268B1 (ru) 2006-08-25
TNSN05006A1 (fr) 2007-05-14
UY27886A1 (es) 2004-02-27
HN2003000206A (es) 2004-07-27
HRP20041196A2 (en) 2005-04-30
BR0312563A (pt) 2005-04-19

Similar Documents

Publication Publication Date Title
CY1112892T1 (el) Δισκιο λασοφοξιφαινης και επικαλυψη του
CY1121877T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει πιμοβενδανη
CY1115289T1 (el) Μεθοδοι αγωγης εναντι ασθενειας που σχετιζεται με φλεγμονη
RS50812B (sr) Suva granulisana kompozicija koja sadrži emtricitabin i tenofovir df
NO20062051L (no) Farmasoytisk virkestoffinneholdende formulering med belegg
BRPI0514738A (pt) derivados de amida de 3-fenil-diidropirimido[4,5-d]pirimidinonas, sua fabricação e aplicação como agentes farmacêuticos
NO20051427L (no) Fremgangsmate for produksjon av hydroksyalkyl stivelsesderivater
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
NO20060847L (no) Substituert 2-aminotetralin til behandling av depresjon
PT1140031E (pt) Preparacao farmaceutica de libertacao controlada com mesilato de tilidina como substancia activa
BRPI0413438A (pt) derivados de pirimidilpirrol ativos como inibidores de cinase
CY1110913T1 (el) Παραγωγα 2-πυρρολιδιν-2-υλο-[1,3,4]-οξαδιαζολης και η χρησιμοποιηση τους σαν αντικαταθλιπτικα
ATE466008T1 (de) P-glycoprotein-inhibitor, verfahren zu dessen herstellung und pharmazeutische zusammensetzung, die diesen enthält
NO304113B1 (no) Krystallinsk tiagabinhydrokloridmonohydrat, farmas°ytisk preparat som omfatter det, og anvendelse derav for fremstilling av et medikament
NO20020282L (no) Nytt difenyl-piperidinderivat
SE0102440D0 (sv) New compound
ATE342264T1 (de) Indolderivate und deren verwendung als gnrh antagonisten
SE0401655D0 (sv) New compounds
PT1109560E (pt) Compostos uteis como inidores de aicarft
MXPA05012679A (es) Nuevos derivados de imidazoles, su preparacion y su uso como medicamento.
EE200100520A (et) N-(2-fenüül-4-aminobutüül)-1-naftamiidid neurokiniin-1-retseptori antagonistidena
NZ515108A (en) Novel ribose-substituted aromatic amides, method for the production and use thereof as medicaments
SG146627A1 (en) Imidazole derivatives
TR200601092T1 (tr) İrbesartan etkin maddesi içeren yeni oral farmasötik formülasyonlar.
NO20022260D0 (no) Stabile farmasöytiske preparater omfattende et benzimidazol og fremgangsmåter for fremstilling derav